Epoetin Alfa HEXAL: Uses, Dosage & Side Effects
A biosimilar erythropoiesis-stimulating agent (ESA) used to treat anemia in chronic kidney disease, cancer chemotherapy, and perioperative settings
Epoetin alfa HEXAL is a biosimilar erythropoiesis-stimulating agent (ESA) containing recombinant human erythropoietin. It is used to stimulate the production of red blood cells in patients with anemia caused by chronic kidney disease (CKD), chemotherapy for certain cancers, or in perioperative settings to reduce the need for blood transfusions. Administered by subcutaneous or intravenous injection, epoetin alfa acts by binding to erythropoietin receptors on bone marrow progenitor cells, promoting their differentiation into mature red blood cells. While highly effective at correcting anemia and improving quality of life, ESA therapy requires careful hemoglobin monitoring to avoid serious cardiovascular complications including thromboembolism, stroke, and heart attack.
Quick Facts: Epoetin Alfa HEXAL
Key Takeaways
- Epoetin alfa HEXAL treats anemia by stimulating red blood cell production: It is a biosimilar version of recombinant human erythropoietin, approved for anemia caused by chronic kidney disease, chemotherapy, and perioperative blood loss reduction.
- Hemoglobin must be carefully monitored: Targeting hemoglobin levels above 11–12 g/dL significantly increases the risk of serious cardiovascular events including stroke, heart attack, blood clots, and death. The lowest effective dose should always be used.
- Iron supplementation is usually essential: Adequate iron stores are required for effective red blood cell production. Most patients need concurrent iron therapy, and ferritin and transferrin saturation should be monitored regularly.
- Cancer patients face additional risks: In patients receiving chemotherapy, ESAs may shorten overall survival and promote tumor progression. Use is restricted to patients with hemoglobin below 10 g/dL receiving palliative chemotherapy.
- Blood pressure must be controlled: Epoetin alfa can raise blood pressure or worsen existing hypertension. Regular blood pressure monitoring is required, and antihypertensive treatment may need to be started or adjusted during therapy.
What Is Epoetin Alfa HEXAL and What Is It Used For?
Epoetin alfa HEXAL is a biosimilar erythropoiesis-stimulating agent (ESA) that contains recombinant human erythropoietin. It stimulates the bone marrow to produce more red blood cells, treating anemia caused by chronic kidney disease, cancer chemotherapy, or planned major surgery.
Erythropoietin (EPO) is a glycoprotein hormone naturally produced primarily by the kidneys in response to low oxygen levels in the blood. It acts on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and survival, ultimately leading to the production of mature red blood cells (erythrocytes). When the kidneys are damaged, as in chronic kidney disease, they produce insufficient erythropoietin, resulting in anemia – a condition characterized by low hemoglobin levels and reduced oxygen-carrying capacity of the blood.
Epoetin alfa HEXAL is a biosimilar medicine, meaning it is highly similar to an already approved biological reference product (Eprex/Erypo). It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells and has the same amino acid sequence and glycosylation pattern as the reference erythropoietin. The European Medicines Agency (EMA) approved Epoetin alfa HEXAL after extensive comparability studies demonstrating equivalent quality, safety, and efficacy to the reference product.
The medication works by binding to erythropoietin receptors (EPO-R) on the surface of erythroid progenitor cells in the bone marrow. This activates the JAK2-STAT5 signaling pathway, which promotes cell survival by preventing apoptosis (programmed cell death) and stimulates the proliferation and differentiation of these precursor cells into mature red blood cells. The resulting increase in red blood cell mass raises hemoglobin levels and improves oxygen delivery to tissues throughout the body.
Approved Indications
Epoetin alfa HEXAL is approved for the treatment of anemia in several clinical contexts, each with specific guidelines and hemoglobin targets:
- Chronic kidney disease (CKD) anemia: Treatment of symptomatic anemia in adult and pediatric patients with CKD, including those on hemodialysis, peritoneal dialysis, or not yet requiring dialysis (pre-dialysis). This is the most common indication and the one for which ESA therapy has the longest track record of clinical use.
- Chemotherapy-induced anemia: Treatment of symptomatic anemia in adult cancer patients receiving chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma. ESA use is restricted to patients with hemoglobin below 10 g/dL and is intended to reduce transfusion requirements.
- Autologous blood predonation programs: Increasing the yield of autologous blood in patients participating in predonation programs before planned major elective surgery, provided they are expected to require a large volume of blood and have hemoglobin between 10 and 13 g/dL.
- Perioperative anemia reduction: Reducing exposure to allogeneic blood transfusions in adult patients without iron deficiency who are scheduled for major elective orthopedic surgery with a high expected blood loss, and who have hemoglobin between 10 and 13 g/dL.
Epoetin alfa HEXAL is a biosimilar, not a generic. Biosimilars undergo a rigorous regulatory pathway that includes analytical, non-clinical, and clinical studies to demonstrate similarity to the reference product. The WHO, EMA, and FDA all have established frameworks for biosimilar approval. Clinical experience with biosimilar epoetins now spans over 15 years, with extensive real-world data confirming their safety and efficacy profile is comparable to the reference products.
How Epoetin Alfa Works in the Body
After subcutaneous injection, epoetin alfa is slowly absorbed into the bloodstream, reaching peak plasma concentrations in approximately 12–18 hours. The subcutaneous route provides more sustained drug levels compared to intravenous administration, which is why it is the preferred route for most non-dialysis patients. The elimination half-life is approximately 19 hours after subcutaneous administration and 4–5 hours after intravenous injection.
The biological response to epoetin alfa follows a predictable timeline. Reticulocytes (immature red blood cells) begin to increase in the blood within 7–10 days of starting treatment, indicating that the bone marrow is responding. Hemoglobin levels typically begin to rise within 2–6 weeks, with the full effect achieved over 8–12 weeks. This delayed response is important for understanding why dose adjustments should not be made too frequently – the clinical guideline is to wait at least 4 weeks before changing the dose.
It is important to understand that epoetin alfa does not work if the body lacks the building blocks for red blood cell production. Iron, vitamin B12, and folate are all essential nutrients required for erythropoiesis. Iron deficiency is the most common cause of inadequate response to ESA therapy, which is why iron status must be assessed before and during treatment. Most patients require concurrent iron supplementation, either oral or intravenous, to achieve and maintain adequate hemoglobin levels.
What Should You Know Before Taking Epoetin Alfa HEXAL?
Before starting epoetin alfa HEXAL, your doctor must evaluate your iron status, blood pressure, and overall cardiovascular risk. The medication is contraindicated in patients with uncontrolled hypertension, pure red cell aplasia following previous ESA therapy, and those unable to receive adequate thromboprophylaxis in the surgical setting.
Epoetin alfa HEXAL is a potent biological agent that requires careful patient selection and monitoring. Your prescribing physician will conduct a thorough assessment before initiating therapy, including a complete blood count, iron studies (serum ferritin and transferrin saturation), blood pressure measurement, and evaluation of potential underlying causes of anemia that should be corrected before starting ESA therapy.
Contraindications – Do Not Use Epoetin Alfa HEXAL If You:
- Are allergic to epoetin alfa or any of the excipients in the formulation
- Have uncontrolled hypertension (high blood pressure that is not adequately treated)
- Have developed pure red cell aplasia (PRCA) following previous treatment with any erythropoiesis-stimulating agent
- Are scheduled for major elective surgery and cannot receive adequate thromboprophylaxis (blood clot prevention)
- Have severe cardiovascular disease including recent heart attack, stroke, or unstable angina (in the surgical indication)
- Are unable to have your blood pressure monitored and managed during treatment
Warnings and Precautions
ESA therapy carries significant risks that require ongoing medical supervision. The following conditions require careful consideration and monitoring during treatment:
- Hypertension: Epoetin alfa can raise blood pressure or worsen existing hypertension, particularly during the initial phase of treatment when hemoglobin is rising rapidly. Blood pressure should be measured regularly, and antihypertensive therapy may need to be initiated or adjusted. In rare cases, hypertensive crisis with encephalopathy-like symptoms (severe headache, confusion, seizures) can occur
- Thromboembolic events: ESAs increase the risk of blood clots (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction), particularly when hemoglobin levels exceed the recommended target. Patients with pre-existing cardiovascular disease, history of thromboembolism, or those who are immobilized are at higher risk
- Pure red cell aplasia (PRCA): In rare cases, patients can develop neutralizing antibodies against erythropoietin, leading to PRCA – a condition where the bone marrow stops producing red blood cells entirely. If PRCA is suspected (sudden loss of efficacy with severe anemia, low reticulocyte count, and anti-erythropoietin antibodies), epoetin alfa must be stopped immediately and no other ESA should be used
- Seizures: Epoetin alfa may lower the seizure threshold, particularly in patients with a history of epilepsy or conditions predisposing to seizures. Avoid driving and operating heavy machinery during the first three months of treatment
- Hepatic impairment: Limited data are available in patients with liver disease. The metabolism of epoetin alfa may be altered, requiring closer monitoring
- Porphyria: Epoetin alfa should be used with caution in patients with porphyria, as it may exacerbate the condition
- Potassium levels: Potassium levels can rise during ESA therapy. Serum potassium should be monitored regularly, especially in patients with chronic kidney disease
Clinical trials (CHOIR, CREATE, TREAT, NHCT) have demonstrated that targeting hemoglobin levels greater than 11–12 g/dL with ESAs increases the risk of death, serious cardiovascular events (stroke, heart attack), and thromboembolic events. In CKD patients, KDIGO guidelines recommend maintaining hemoglobin between 10 and 11.5 g/dL and not intentionally exceeding 13 g/dL. Always use the lowest dose sufficient to reduce the need for blood transfusions.
In multiple clinical studies, ESAs administered to cancer patients have been associated with shortened overall survival and/or increased risk of tumor progression when hemoglobin targets exceeded 12 g/dL. ESAs are not indicated for the treatment of anemia in cancer patients who are not receiving concurrent myelosuppressive chemotherapy. The decision to use ESAs in cancer patients should carefully weigh the risks against the benefits of avoiding transfusions.
Pregnancy and Breastfeeding
There are limited data on the use of epoetin alfa in pregnant women. Animal reproduction studies have shown adverse effects on the fetus at high doses. Epoetin alfa HEXAL should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
It is not known whether epoetin alfa is excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or discontinue treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Caution should be exercised when epoetin alfa HEXAL is administered to a breastfeeding woman.
Children and Adolescents
Epoetin alfa HEXAL is approved for the treatment of anemia associated with chronic kidney disease in children from birth onwards. The dosing requirements in children are generally higher than in adults on a weight-adjusted basis, particularly in young children. Careful monitoring of hemoglobin levels, growth, and development is recommended. Epoetin alfa HEXAL is not approved for chemotherapy-induced anemia in pediatric patients due to insufficient safety and efficacy data in this population.
How Does Epoetin Alfa HEXAL Interact with Other Drugs?
Epoetin alfa HEXAL has a limited number of direct drug interactions, but several medications can affect its efficacy or increase certain risks. The most important interactions involve iron supplementation (essential for efficacy), anticoagulants (dosing may need adjustment as hematocrit rises), and ACE inhibitors (may reduce ESA response).
Unlike many small-molecule drugs, epoetin alfa is a large glycoprotein that is not metabolized by hepatic cytochrome P450 enzymes, so it does not share the broad interaction profile of drugs processed through these pathways. However, clinically important interactions exist because of the physiological changes that occur when hemoglobin and hematocrit rise during treatment. As blood viscosity increases and red blood cell mass expands, the pharmacokinetics and pharmacodynamics of other medications can be affected.
Major Interactions (Clinically Significant)
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Iron supplements (oral & IV) | Essential co-therapy | Iron is required for effective erythropoiesis. Functional iron deficiency is the most common cause of inadequate ESA response. Monitor ferritin and transferrin saturation; supplement as needed. |
| Anticoagulants (heparin, warfarin) | Dose adjustment needed | Rising hematocrit increases blood viscosity, which may require adjustment of heparin dose during dialysis. Warfarin patients may need more frequent INR monitoring as ESA therapy alters blood composition. |
| ACE inhibitors | Reduced ESA response | ACE inhibitors (e.g., enalapril, ramipril) can inhibit erythropoiesis by reducing the breakdown of Ac-SDKP, a natural inhibitor of red blood cell production. Higher ESA doses may be needed. |
| Angiotensin II receptor blockers | Reduced ESA response | Similar mechanism to ACE inhibitors. May reduce erythropoietic response and require higher ESA doses. |
| Cyclosporine | Increased cyclosporine binding | Cyclosporine binds to red blood cells. As hematocrit rises, cyclosporine blood levels may change. Monitor cyclosporine levels and adjust dose accordingly. |
Minor Interactions and Considerations
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Antihypertensives | Blood pressure changes | ESA therapy can raise blood pressure. Antihypertensive medication may need to be started or doses increased. Monitor BP regularly. |
| Antiepileptic drugs | Potential seizure risk | ESAs may lower seizure threshold. Patients on antiepileptic drugs should be monitored closely, especially during the first months of therapy. |
| Potassium-sparing agents | Hyperkalemia risk | Potassium levels can rise during ESA therapy. Combined use with potassium-sparing diuretics or potassium supplements requires monitoring. |
| Folic acid & Vitamin B12 | Supporting co-therapy | Deficiency of these vitamins impairs erythropoiesis and reduces ESA effectiveness. Check levels before starting ESA therapy and supplement if deficient. |
What Is the Correct Dosage of Epoetin Alfa HEXAL?
Dosage of epoetin alfa HEXAL is highly individualized based on the clinical indication, patient weight, hemoglobin response, and target hemoglobin range. Treatment should always use the lowest dose necessary to avoid transfusions and maintain hemoglobin within the recommended range of 10–12 g/dL.
Epoetin alfa HEXAL dosing follows a principle of individualized therapy. The starting dose, route of administration, and frequency vary depending on whether the patient has chronic kidney disease, is receiving chemotherapy, or is being treated in a perioperative setting. In all cases, the dose should be titrated gradually based on hemoglobin response, with the goal of using the lowest effective dose. Hemoglobin should not be allowed to rise by more than 2 g/dL over a four-week period, as rapid increases are associated with higher cardiovascular risk.
Adults with Chronic Kidney Disease
Hemodialysis Patients
Starting dose: 50 IU/kg three times per week, administered intravenously during dialysis sessions. The dose is adjusted by 25 IU/kg increments at intervals of at least 4 weeks. The maintenance dose ranges from 75–300 IU/kg per week, divided into 2–3 doses. Maximum individual dose should not exceed 300 IU/kg three times per week.
Pre-dialysis and Peritoneal Dialysis Patients
Starting dose: 50 IU/kg two to three times per week, administered subcutaneously. The subcutaneous route is preferred for these patients as it provides more stable drug levels and is more convenient. Dose adjustments follow the same principles, with increases of 25 IU/kg at 4-week intervals. Maintenance doses typically range from 17–200 IU/kg per week.
Adults with Cancer (Chemotherapy-Induced Anemia)
Chemotherapy Patients
Starting dose: 150 IU/kg three times per week, administered subcutaneously. Alternatively, 450 IU/kg once weekly may be used. If hemoglobin has increased by at least 1 g/dL after 4 weeks, continue the same dose. If hemoglobin has not increased by at least 1 g/dL after 4 weeks, increase to 300 IU/kg three times per week. If after an additional 4 weeks at the higher dose there is still inadequate response, discontinue treatment. Do not exceed hemoglobin of 12 g/dL. Discontinue therapy 4 weeks after the end of the chemotherapy course.
Perioperative Setting
Pre-surgical Blood Conservation
Dose: 600 IU/kg given subcutaneously twice weekly for 3 weeks before surgery. Alternatively, 300 IU/kg daily for 10 days before surgery, on the day of surgery, and for 4 days after surgery. Adequate iron supplementation must be given throughout treatment. All patients should receive thromboprophylaxis during the perioperative period.
Children with Chronic Kidney Disease
Pediatric CKD Patients
Starting dose: 50 IU/kg three times per week, administered intravenously (hemodialysis patients) or subcutaneously (other patients). Children generally require higher doses per kilogram than adults, particularly children under 5 years. Dose adjustments follow the same principles as adults, but with closer monitoring of hemoglobin levels, growth, and development. Maximum dose is not well-established but individual requirements may exceed adult weight-based doses.
Missed Dose
If you miss a dose of epoetin alfa HEXAL, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. If you are unsure what to do, contact your doctor or nurse for advice. Missing occasional doses should not significantly affect your hemoglobin level, but consistently missing doses will lead to a decline in hemoglobin over time.
Overdose
The therapeutic margin of epoetin alfa is wide, and single overdoses are unlikely to cause immediate harm. However, an excessive dose can lead to an exaggerated pharmacological effect – primarily polycythemia (excessively high hemoglobin and hematocrit), which significantly increases the risk of thromboembolic events including stroke, heart attack, deep vein thrombosis, and pulmonary embolism. If hemoglobin rises above 12 g/dL, the dose should be reduced or temporarily withheld. If polycythemia develops, treatment should be stopped immediately, and phlebotomy (blood removal) may be required. There is no specific antidote for epoetin alfa overdose.
What Are the Side Effects of Epoetin Alfa HEXAL?
The most common side effects of epoetin alfa HEXAL are hypertension, headache, and flu-like symptoms (particularly at the start of treatment). Serious but less common side effects include thromboembolic events (blood clots, stroke, heart attack), pure red cell aplasia, and hypertensive crises. The risk of serious side effects increases when hemoglobin targets exceed 12 g/dL.
Like all medicines, epoetin alfa HEXAL can cause side effects, although not everybody gets them. The side effect profile is related to both the pharmacological action of the drug (stimulating red blood cell production and the resulting increase in blood viscosity and blood pressure) and to the injection itself. Most side effects are mild to moderate and resolve with continued treatment or dose adjustment. However, some adverse effects are serious and require immediate medical attention.
The frequency of side effects varies between different patient populations. Patients with chronic kidney disease, particularly those on hemodialysis, experience different side effects compared to cancer patients receiving chemotherapy. The following frequency categories are based on clinical trial data and post-marketing surveillance:
Very Common (affects more than 1 in 10 people)
- Headache (especially at the start of treatment)
- Hypertension (high blood pressure) or worsening of existing high blood pressure
- Flu-like symptoms (fever, chills, muscle aches, fatigue) – more common after the first injections
- Joint pain (arthralgia)
- Injection site reactions (pain, redness, swelling at the injection site)
- Nausea (in cancer patients receiving chemotherapy)
- Diarrhea (in cancer patients receiving chemotherapy)
Common (affects 1 to 10 in 100 people)
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Skin rash or urticaria (hives)
- Cough
- Seizures (particularly in CKD patients)
- Vascular access thrombosis (in hemodialysis patients – clotting of the dialysis shunt)
- Dizziness
- Upper respiratory tract infections
- Hyperkalemia (elevated potassium levels)
Uncommon (affects 1 to 10 in 1,000 people)
- Hypertensive crisis (dangerously high blood pressure with encephalopathy-like symptoms)
- Stroke or transient ischemic attack (TIA)
- Myocardial infarction (heart attack)
- Severe allergic reactions (anaphylaxis)
- Thrombocytosis (elevated platelet count)
Rare (affects fewer than 1 in 1,000 people)
- Pure red cell aplasia (PRCA) – antibody-mediated cessation of red blood cell production
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Porphyria exacerbation
- Severe anaphylactic reactions with angioedema and bronchospasm
Contact your doctor or go to the emergency department immediately if you experience: severe headache with confusion, visual disturbances, or seizures (signs of hypertensive crisis); sudden numbness or weakness on one side of the body, difficulty speaking, or sudden vision loss (signs of stroke); chest pain, shortness of breath, or swelling of one leg (signs of blood clot or heart attack); severe allergic reaction with swelling of the face, throat, or tongue, difficulty breathing, or widespread rash; sudden severe drop in hemoglobin with fatigue and pallor (possible sign of PRCA).
Managing Common Side Effects
Many of the common side effects of epoetin alfa HEXAL can be managed with simple measures. Flu-like symptoms typically improve within the first few weeks of treatment and can be alleviated with paracetamol (acetaminophen). Injection site reactions can be minimized by rotating injection sites and allowing the pre-filled syringe to reach room temperature before injection. Headaches at the start of treatment are often related to the rising hemoglobin and usually resolve as levels stabilize. Blood pressure should be monitored regularly, and your doctor will adjust antihypertensive medications as needed.
How Should You Store Epoetin Alfa HEXAL?
Epoetin alfa HEXAL must be stored in the refrigerator at 2–8°C. Do not freeze. Keep the pre-filled syringes in the outer carton to protect from light. The product may be removed from the refrigerator for a single period of up to 3 days at room temperature (not above 25°C).
Proper storage of epoetin alfa HEXAL is essential to maintain its efficacy and safety. As a biological product (a protein), it is sensitive to temperature extremes, light exposure, and physical agitation. Incorrect storage can lead to protein denaturation, aggregation, or loss of biological activity, which may reduce effectiveness or increase the risk of immunogenic reactions (formation of anti-erythropoietin antibodies).
- Refrigeration required: Store at 2–8°C (36–46°F) in a refrigerator. Do not place near the freezer compartment
- Do not freeze: Freezing will damage the protein and render the product unusable. If the product has been accidentally frozen, it must be discarded
- Light protection: Keep the pre-filled syringes in the original outer carton to protect from light
- Room temperature excursion: The product may be removed from the refrigerator for a single period of up to 3 days at room temperature (not above 25°C/77°F). If not used within this period, it must be discarded and not returned to the refrigerator
- Do not shake: Vigorous shaking can cause protein aggregation. Handle gently
- Check before use: Before injection, visually inspect the solution. It should be clear and colorless. Do not use if the solution is cloudy, contains particles, or appears discolored
- Keep out of reach of children
- Do not use after the expiry date printed on the carton and syringe label
When traveling with epoetin alfa HEXAL, use an insulated cool bag with ice packs to maintain refrigerated temperature during transport. Avoid exposing the syringes to direct sunlight or extreme temperatures. If you travel by air, carry the medication in your hand luggage along with a letter from your doctor confirming that you need to carry injectable medication.
What Does Epoetin Alfa HEXAL Contain?
Each pre-filled syringe of Epoetin alfa HEXAL 10,000 IU/1 mL contains 10,000 international units (83.4 micrograms) of epoetin alfa as the active ingredient, produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The solution also contains several excipients to stabilize the protein and maintain appropriate pH.
Active Ingredient
The active substance is epoetin alfa, a 165-amino acid glycoprotein produced using recombinant DNA technology. Each 1 mL pre-filled syringe contains 10,000 IU (international units), corresponding to 83.4 micrograms of epoetin alfa. The protein is glycosylated with both N-linked and O-linked carbohydrate chains, which are essential for its biological activity and in vivo half-life. The molecular weight of the glycosylated protein is approximately 30,400 daltons.
Excipients (Inactive Ingredients)
- Sodium dihydrogen phosphate dihydrate: Buffer component to maintain pH
- Disodium hydrogen phosphate dihydrate: Buffer component to maintain pH
- Sodium chloride: Tonicity-adjusting agent to make the solution isotonic
- Polysorbate 20: Surfactant to prevent protein aggregation and adsorption
- Glycine: Stabilizing amino acid to protect the protein during storage
- Leucine: Stabilizing amino acid
- Isoleucine: Stabilizing amino acid
- Threonine: Stabilizing amino acid
- Glutamic acid: Stabilizing amino acid
- Phenylalanine: Stabilizing amino acid (important: patients with phenylketonuria should be informed)
- Water for injections: Solvent
Epoetin alfa HEXAL contains phenylalanine as an excipient. This is relevant for patients with phenylketonuria (PKU), who must limit their phenylalanine intake. The amount per dose is very small (less than 1 mg per syringe), but patients with PKU should be informed and the intake accounted for in their dietary management.
Presentation
Epoetin alfa HEXAL is supplied as a clear, colorless solution for injection in pre-filled syringes. Each syringe is equipped with a needle guard mechanism for safe disposal after use. The syringes are individually packaged in blister packs within an outer carton. Multiple strength presentations are available (1,000 IU, 2,000 IU, 3,000 IU, 4,000 IU, 5,000 IU, 6,000 IU, 8,000 IU, 10,000 IU, 20,000 IU, 30,000 IU, and 40,000 IU), though not all pack sizes may be marketed in every country.
Frequently Asked Questions
Epoetin alfa HEXAL is used to treat anemia (low red blood cell count) caused by chronic kidney disease (in both dialysis and pre-dialysis patients), chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma, and to reduce the need for blood transfusions in adults undergoing major elective surgery. It works by stimulating the bone marrow to produce more red blood cells, mimicking the action of natural erythropoietin that is produced by the kidneys.
Epoetin alfa HEXAL is administered as an injection, either subcutaneously (under the skin, usually in the abdomen or thigh) or intravenously (into a vein, typically during dialysis). Patients on hemodialysis usually receive intravenous injections during their dialysis sessions. Pre-dialysis patients and cancer patients typically receive subcutaneous injections, which can be self-administered at home after proper training by a healthcare professional. The pre-filled syringes include a needle guard for safe disposal.
The most serious risks include thromboembolic events (blood clots, stroke, heart attack), particularly when hemoglobin levels exceed 12 g/dL. In cancer patients, ESAs may shorten overall survival and promote tumor progression. Pure red cell aplasia (PRCA), a rare but serious condition where the body stops producing red blood cells entirely due to antibodies against erythropoietin, can also occur. Hypertensive crises with encephalopathy-like symptoms (severe headache, confusion, seizures) are another serious risk. Regular monitoring of hemoglobin and blood pressure is essential.
According to KDIGO guidelines for CKD patients, the target hemoglobin range is generally 10–11.5 g/dL, and treatment should not intentionally exceed 13 g/dL. For cancer patients receiving chemotherapy, the goal is to maintain hemoglobin just high enough to avoid transfusions, and ESA therapy should be stopped once chemotherapy ends. The principle is always to use the lowest effective dose. Your doctor will individualize the target based on your specific health situation, symptoms, and cardiovascular risk factors.
Yes, subcutaneous injections of Epoetin alfa HEXAL can be self-administered at home after receiving proper training from a healthcare professional. You will be taught how to prepare and inject the medication correctly, how to rotate injection sites, and how to safely dispose of used syringes. However, intravenous administration must be performed by a healthcare professional. Even during home self-administration, you will still need to attend regular clinic appointments for blood tests to monitor hemoglobin levels and adjust your dosing.
Iron is a fundamental building block for hemoglobin, the oxygen-carrying protein in red blood cells. When epoetin alfa stimulates increased red blood cell production, the body’s iron demand rises significantly. Without adequate iron stores, the medication cannot work effectively – a condition called functional iron deficiency. Most patients need iron supplementation, either oral tablets or intravenous iron infusions, during ESA therapy. Your doctor will monitor your ferritin levels and transferrin saturation to ensure your iron stores are adequate, typically aiming for ferritin above 100 ng/mL and transferrin saturation above 20%.
References
- European Medicines Agency (EMA). Epoetin alfa HEXAL – Summary of Product Characteristics. EMA. Available at: ema.europa.eu.
- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Supplements. 2012;2(4):279–335. doi: 10.1038/kisup.2012.37.
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease (CHOIR trial). New England Journal of Medicine. 2006;355(20):2085–2098.
- Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia (CREATE trial). New England Journal of Medicine. 2006;355(20):2071–2084.
- Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease (TREAT trial). New England Journal of Medicine. 2009;361(21):2019–2032.
- Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–4059.
- Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine. 2010;153(1):23–33.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- British National Formulary (BNF). Epoetin alfa. National Institute for Health and Care Excellence. Available at: bnf.nice.org.uk.
- Locatelli F, Barany P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease. Nephrology Dialysis Transplantation. 2013;28(6):1346–1359.
Editorial Team
Written by iMedic Medical Editorial Team – specialists in clinical pharmacology, nephrology, and hematology with expertise in erythropoiesis-stimulating agents and anemia management.
Reviewed by iMedic Medical Review Board – an independent panel of physicians and pharmacists who verify accuracy according to KDIGO, EMA, FDA, and WHO guidelines.
All medical claims are supported by Level 1A evidence from systematic reviews and randomized controlled trials, including the CHOIR, CREATE, and TREAT landmark studies.
iMedic receives no funding from pharmaceutical companies. All content is independently produced without commercial influence or advertising.